CADL Stock Overview
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Candel Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.54 |
52 Week High | US$1.95 |
52 Week Low | US$0.66 |
Beta | 0.96 |
1 Month Change | -13.48% |
3 Month Change | 10.79% |
1 Year Change | 9.17% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -78.00% |
Recent News & Updates
Shareholder Returns
CADL | US Biotechs | US Market | |
---|---|---|---|
7D | 2.7% | 0.9% | 0.4% |
1Y | 9.2% | 10.3% | 28.8% |
Return vs Industry: CADL matched the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: CADL underperformed the US Market which returned 29.5% over the past year.
Price Volatility
CADL volatility | |
---|---|
CADL Average Weekly Movement | 12.0% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CADL's share price has been volatile over the past 3 months.
Volatility Over Time: CADL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 76 | Paul-Peter Tak | https://www.candeltx.com |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma.
Candel Therapeutics, Inc. Fundamentals Summary
CADL fundamental statistics | |
---|---|
Market cap | US$44.54m |
Earnings (TTM) | -US$31.93m |
Revenue (TTM) | US$31.00k |
1,437x
P/S Ratio-1.4x
P/E RatioIs CADL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CADL income statement (TTM) | |
---|---|
Revenue | US$31.00k |
Cost of Revenue | US$21.56m |
Gross Profit | -US$21.53m |
Other Expenses | US$10.40m |
Earnings | -US$31.93m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.10 |
Gross Margin | -69,438.71% |
Net Profit Margin | -102,990.32% |
Debt/Equity Ratio | 91.9% |
How did CADL perform over the long term?
See historical performance and comparison